<DOC>
	<DOCNO>NCT02618941</DOCNO>
	<brief_summary>This follow-up study ass safety clinical activity continue AFFITOPE速 PD01A vaccination patient Parkinson 's disease . Patients , already participated AFF008 program involve receive second boost immunization AFFITOPE速 PD01A . One study site Vienna ( Austria ) involve . In addition , 6 patient offer participation within untreated control Group .</brief_summary>
	<brief_title>Follow-up Study Assess Second Boost Immunization With AFFITOPE速 PD01A With Regard Safety Clinical Activity ( AFF008AA )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Prior participation AFF008 , AFF008E AFF008A Written inform consent sign dated patient , preferentially , caregiver In investigator 's opinion , visual auditory impairment would reduce patient ' ability complete study questionnaire unable receive instruction These Female patient childbearing potential eligible use medically accept contraceptive method All change conventional PD therapy must available sponsor ; particular pharmacologic symptomatic PD medication allow transformation Levodopa standard dose A potential participant stable dos medication he/she take consist illness accord medical history ( except PD therapy , record separately ) least 30 day prior Visit 1 consider relevant investigator Women childbearing potential without birth control pregnant woman Participation another clinical trial within 3 month Visit 1 ( except AFF008A ) History questionable compliance visit schedule ; patient expect complete clinical trial Autoimmune disease allergy component vaccine History cancer ( Exceptions : nonmelanoma skin cancer , intraepithelial cervical neoplasia ) Active infectious disease ( e.g. , Hepatitis B , C ) Immunodeficiency Significant systemic illness Alcoholism substance abuse Prior and/or current treatment experimental immunotherapeutics include IVIG exception AFFITOPE速 PD01A , immune modulate drug treatment deep brain stimulation Venous status render impossible place i.v . access</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>